FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, has appointed Dr. Dirk Beher as Chief Executive Officer and Executive Board member.   Beher assumes this role from Dr. Thomas Schulze, who co-founded FundaMental and has been at the helm since its inception. Schulze will transition to the Board of Directors as part of a planned succession strategy. About Dr. Beher Beher brings a we...